There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood Therapeutics (NASDAQ:GBT) and Staar Surgical Company (NASDAQ:STAA) with bullish sentiments.
Global Blood Therapeutics (GBT)
In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Global Blood Therapeutics, with a price target of $96. The company’s shares opened today at $43.65.
Piros said:
“We reaffirm our Overweight rating and $96 12-month price target for GBT. Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.7 billion ($88/share), and our estimate of YE18 cash of $424 million ($8/share).”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -7.0% and a 40.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Bellicum Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $85 average price target, implying a 94.7% upside from current levels. In a report issued on July 27, H.C. Wainwright also maintained a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
Staar Surgical Company (STAA)
In a report released today, Chris Cooley from Stephens reiterated a Buy rating on Staar Surgical Company, with a price target of $40. The company’s shares opened today at $38.75, close to its 52-week high of $43.15.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 33.0% and a 75.4% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, DENTSPLY SIRONA Inc, and Insulet Corp.
Currently, the analyst consensus on Staar Surgical Company is a Moderate Buy with an average price target of $32, implying a -17.4% downside from current levels. In a report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $43 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
